Woodside formed to further LB's research
Raises $40MM
Raises $40MM
First Generation ReliefBand Developed
FDA clearance approved in four major clinical markets: Pregnancy Induced Nausea and Vomiting (PINV), Chemotherapy Induced Nausea and Vomiting (CINV), as an adjunct to anti-emetics in Post Operative Nausea and Vomiting (PONV), and Motion Sickness Induced Nausea and Vomiting (MSNV)
FDA approved for pregnancy induced nausea and vomiting (morning sickness) & motion induced nausea and vomiting (motion sickness)
FDA clearance approved in four major clinical markets: Pregnancy Induced Nausea and Vomiting (PINV), Chemotherapy Induced Nausea and Vomiting (CINV), as an adjunct to anti-emetics in Post Operative Nausea and Vomiting (PONV), and Motion Sickness Induced Nausea and Vomiting (MSNV)
FDA approved for pregnancy induced nausea and vomiting (morning sickness) & motion induced nausea and vomiting (motion sickness)
Second Generation ReliefBand Developed
Used by over 250 hospitals
Used by over 250 hospitals
Abbot acquires Woodside
Numerous clinical publications and hospital based clinical validation of technology platforms of PONV, PINV and CINV
NMT acquires all Woodside assets
Neurowave Medical Technologies is born
Leverage existing knowledge & relationships to quickly re-start Woodside
Neurowave Medical Technologies is born
Leverage existing knowledge & relationships to quickly re-start Woodside
